Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR139 | Q6DWJ6 | 20/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL22092064 | 0.92 | GPR139 (0.36) | GPR139 | |
| SCHEMBL22092063 | 0.82 | GPR139 (0.41) | GPR139 | |
| SCHEMBL22092249 | 0.81 | GPR139 (0.48) | GPR139 | |
| SCHEMBL22098776 | 0.77 | FLT3 (0.41) | GPR139 | |
| SCHEMBL22092081 | 0.77 | GPR139 (0.38) | GPR139 | |
| SCHEMBL22092073 | 0.76 | GRM2 (0.42) | — | |
| SCHEMBL22092133 | 0.76 | GPR139 (0.49) | GPR139 | |
| SCHEMBL22092071 | 0.75 | GPR139 (0.40) | GPR139 | |
| SCHEMBL22092061 | 0.75 | PRMT5 (0.39) | GPR139 | |
| Trifluoroacetic Acid SCHEMBL22092129 | 0.75 | GPR139 (0.45) | GPR139 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820769-B2 | Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2023-11-21 | — | — | US | claimed |
| US-20220024918-A1 | TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2022-01-27 | — | — | US | claimed |
| US-11091479-B2 | Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2021-08-17 | — | — | US | claimed |
| US-20200223844-A1 | TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2020-07-16 | — | — | US | claimed |
| US-11820769-B2 | Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2023-11-21 | — | — | US | disclosed |
| US-11820769-B2 | Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2023-11-21 | — | — | US | disclosed |
| US-11820769-B2 | Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2023-11-21 | — | — | US | disclosed |
| US-20220024918-A1 | TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2022-01-27 | — | — | US | disclosed |
| US-20220024918-A1 | TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2022-01-27 | — | — | US | disclosed |
| US-11091479-B2 | Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2021-08-17 | — | — | US | disclosed |
| US-11091479-B2 | Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2021-08-17 | — | — | US | disclosed |
| US-20200223844-A1 | TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2020-07-16 | — | — | US | disclosed |
| US-20200223844-A1 | TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2020-07-16 | — | — | US | disclosed |
| WO-2020121263-A1 | TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2020-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091479-B2 | Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same | VAPB, HDLBP, VAPA | GPR139 4033/4885 |
| US-11820769-B2 | Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same | VAPB, HDLBP, VAPA | GPR139 4033/4885 |
| US-20200223844-A1 | TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | VAPB, HDLBP, VAPA | GPR139 4033/4885 |
| US-20220024918-A1 | TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | VAPB, HDLBP, VAPA | GPR139 4033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.